Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- October31 2004
- Volume 11
- Issue 20
Solid Buy-and-Holders
Author(s)Michael Sheehan
Advertisement
The Outlook
Note:
One of the oldest and wisest pieces ofinvestment advice is to invest in solidcompanies for the long haul. Accordingto financial experts at (800-852-1641), physician-investors shouldconsider the following stocks as solidlong-term, not short-term, investments:Anheuser-Busch Cos Inc, AutomaticData Processing Inc, Citigroup Inc, FifthThird Bancorp, Johnson & Johnson,MBNA Corp, Pepsico Inc, Sysco Corp,Walgreen Co, and WM Wrigley Jr Co.Never invest in a stock withoutcompleting a thorough research effort.
Articles in this issue
about 18 years ago
A Life of Caring Ended Too Quicklyabout 18 years ago
Health Care Cost Controls—for Allabout 18 years ago
Making Moneyabout 18 years ago
How to Mourn for Your Departed Moneyabout 18 years ago
Physician Recruitment: A Look at Job Trendsabout 18 years ago
Are You Facing a Medical Career Crisis?about 18 years ago
Consider a Path for Your Journey's Endabout 18 years ago
Ponder the State of Pension Plans Todayabout 18 years ago
Portfolio CHECK-UPabout 18 years ago
Why Insured Munis?Advertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5